Page 436 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 436

Appendix Table C3.2. KQ3 multivariable analyses (continued)
                                            Author          Factors       Data source      Duration      Analyzed         Population         WW/AS          Methods          Results as described in paper
                                              yr                                                          sample        characteristics  definitions
                                             PMI
                                        Yan 177           Clinical       Survey of         1989-       1809 of 2345     Screen-            Not            Multinomial      1. Non-Black more likely (than
                                        2000                             men               1998        provided         detected,          explicitly     logistic         Black) to choose RP than WW
                                        10699903                         diagnosed                     followup         clinically         provided       regression       [OR=4.3 (1.7, 10.9)] or
                                                                         with prostate                 questionnaire  localized                           (WW vs. RP       (nonsignificantly) RT than WW
                                                                         cancer                        information      prostate cancer                   vs. RT)          [OR=2.6 (0.86, 7.7)]
                                                                         (through the                                                                                      2. Clinical stage T2 more likely
                                                                         Washington                                                                                        (than T1) to choose RP than WW
                                                                         U. PSA                                                                                            [OR=3.0 (1.8, 4.8)] or RT than WW
                                                                         Prostate                                                                                          [OR=2.8 (1.6, 4.7)]
                                                                         Cancer                                                                                            3. No urinary dysfunction more
                                                                         Screening                                                                                         likely (than yes) to choose RP than
                                                                         Program) who                                                                                      WW [OR=1.8 (1.13, 2.8)] but NS
                                                                         chose 1 of 3                                                                                      RT vs. WW [OR=1.08 (0.66-1.8)]
                                                                         tx (RP, RT or                                                                                     4. No sexual dysfunction NS RP
                                                                         WW)                                                                                               vs. WW [OR=0.83 (0.5, 1.3)] but
                                                                                                                                                                           less likely to choose RT than WW
                                                                                                                                                                           [OR=0.52 (0.30, 0.84)]
                                                                                                                                                                           5. PSA level, for every 1 ng/mL
                                                                                                                                                                           increase (at dx) RP more likely
                                                                                                                                                                           than WW [OR=1.12 (1.04, 1.20)]
                                                                                                                                                                           and RT than WW [OR=1.15 (1.07,
                                                                                                                                                                           1.23)]
                                                                                                                                                                           6. Age, for every 5-yr increase RP
                                                                                                                                                                           less likely than WW [OR=0.21
                                                                                                                                                                           (0.17, 0.27)] and RT less likely
                                                                                                                                                                           than WW [OR=0.49 (0.39, 0.63)]

                                                                                                                                                                           NS: marital status, education,
                                                                                                                                                                           income, indication for biopsy, and
                                                                                                                                                                           a Charlson-like comorbidity score.




















                                                                                                                        C-136
   431   432   433   434   435   436   437   438   439   440   441